Raygent.com

This article was published in Genetic Engineering News in the section “Wall Street Biobeat” on April 1, 2011. Monoclonal antibody therapies remain the dominant technology with immunotherapy and stem cell therapies on the horizon. GEN | Articles: Innovations Continue to Drive Market Gains Emerging Technologies in Biomedicine-Continuing Series Published in Genetic Engineering News April 1 [...]

Biologics for Treatment of Cancer and Prevention of Infectious Disease Amgen(AMGN) and  Biovex said today that both Boards approved the sale of privately held Biovex for $425M with milestone payments as much as $525M. The Biovex lead product OncoVex, an oncolytic vaccine, is in a Phase III multinational study for metastatic melanoma. A second study [...]